Wolfgang Dummer - 04 Nov 2021 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP & CMO
Signature
/s/ Dolly Vance (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
04 Nov 2021
Net transactions value
$0
Form type
4
Filing time
05 Nov 2021, 18:59:30 UTC
Next filing
26 Jan 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Stock Option (Right to Buy) Award $0 +37,500 $0.000000 37,500 04 Nov 2021 Common Stock 37,500 $2.38 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was granted a performance-based option to purchase 37,500 shares of common stock on August 25, 2020. Thus, the exercise price of this option is $2.38 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On November 4, 2021, it was determined that the performance metric had been met.
F2 The shares of common stock subject to the option vest in equal monthly installments over twenty-four (24) months from the vesting commencement date of October 25, 2021, subject to the reporting person's continuous service to the issuer through each such period.